K
Karla V. Ballman
Researcher at Cornell University
Publications - 390
Citations - 34158
Karla V. Ballman is an academic researcher from Cornell University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 78, co-authored 353 publications receiving 29127 citations. Previous affiliations of Karla V. Ballman include University of South Florida & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Brachytherapy improves outcomes in young men (≤60 years) with prostate cancer: A SEER analysis.
Hani Ashamalla,Adel Guirguis,Kyle McCool,Shauna McVorran,Malcolm D. Mattes,Daniel Metzger,Clara Oromendia,Karla V. Ballman,B. Mokhtar,Mounzer Tchelebi,Evangelia Katsoulakis,Sameer Rafla +11 more
TL;DR: In men ≤60 years of age with prostate cancer, radiation therapy continues to offer excellent outcomes and the use of brachytherapy was associated with reduced PCSM compared to treatment with EBRT alone.
Journal ArticleDOI
Prognostic value of the SPOP mutant genomic subclass in prostate cancer
Jonathan Shoag,Deli Liu,Xiaoyue Ma,Clara Oromendia,Paul J. Christos,Karla V. Ballman,Cynthia Angulo,Peter Y. Cai,Christopher Gaffney,Eric A. Klein,Jeffrey Karnes,Robert B. Den,Yang Liu,Elai Davicioni,Christopher E. Barbieri +14 more
TL;DR: The clinical utility of delineating any single molecular alteration in prostate cancer remains unclear, but the importance of genomic subtypes in prostatecancer behavior and potential role in prognostic tools is illustrated.
Journal ArticleDOI
Joint estimation of calibration and expression for high-density oligonucleotide arrays
TL;DR: A unified algorithm which incorporates normalization and class comparison in one analysis using probe level perfect match and mismatch data is presented, based on calibration models common to most biological assays, and the resulting chip-specific parameters have a natural interpretation.
Journal ArticleDOI
IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831.
Monica M. Reinholz,Beiyun Chen,Amylou C. Dueck,Kathleen S. Tenner,Karla V. Ballman,Darren L. Riehle,Robert B. Jenkins,Xochiquetzal J. Geiger,Ann E. McCullough,Edith A. Perez +9 more
TL;DR: In contrast to preclinical studies that suggest a decrease in trastuzumab sensitivity in IGF1R+ tumors, adjuvant data show benefit of adding trastizumab for patients with either IGF1 R+ and IGF1r− breast tumors.